Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.

被引：5
|
作者：
Mansoor, Wasat [1 ]
Kulkarni, Amit S. [2 ]
Kato, Ken [3 ]
Sun, Jong-Mu [4 ]
Shah, Manish A. [5 ]
Enzinger, Peter C. [6 ]
Adenis, Antoine [7 ]
Doi, Toshihiko [8 ]
Kojima, Takashi [9 ,10 ]
Metges, Jean-Philippe
Li Zhigang [11 ]
Kim, Sung-Bae [12 ]
Cho, Byoung Chul [13 ]
Sunpaweravong, Patrapim [14 ]
Alsina, Maria [15 ,16 ]
Goekkurt, Eray [17 ,18 ]
Suryawanshi, Shailaja [2 ]
Norquist, Josephine [2 ]
Shah, Sukrut [2 ]
Shen Lin [19 ]
机构：
[1] Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Natl Canc Ctr, Tokyo, Japan
[4] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[5] Weill Cornell Med, New York, NY USA
[6] Dana Farber Canc Inst, Ctr Esophageal & Gastr Canc, Boston, MA 02115 USA
[7] Univ Montpellier, IRCM, INSERM, ICM, Montpellier, France
[8] Natl Canc Ctr Hosp East, Chiba, Japan
[9] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[10] CHU Brest, Inst Cancerol & Hematol ARPEGO Network, Brest, France
[11] Shanghai Chest Hosp Esophageal Dis Ctr, Shanghai, Peoples R China
[12] Asan Med Ctr, Seoul, South Korea
[13] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea
[14] Prince Songkla Univ Hosp, Songkhla, Thailand
[15] Vall dHebron Univ Hosp, Barcelona, Spain
[16] Inst Oncol VCIO, Barcelona, Spain
[17] Hematol Oncol Practice Eppendorf, Hamburg, Germany
[18] Univ Canc Ctr Hamburg, Hamburg, Germany
[19] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.168
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
    Kato, K.
    Sun, J-M.
    Shah, M. A.
    Enzinger, P. C.
    Adenis, A.
    Doi, T.
    Kojima, T.
    Metges, J-P.
    Li, Z.
    Kim, S-B.
    Cho, B. C. Chul
    Mansoor, W.
    Li, S-H.
    Sunpaweravong, P.
    Maqueda, M. A.
    Goekkurt, E.
    Liu, Q.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1192 - S1193
  • [2] KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer
    Kato, Ken
    Shah, Manish A.
    Enzinger, Peter
    Bennouna, Jaafar
    Shen, Lin
    Adenis, Antoine
    Sun, Jong-Mu
    Cho, Byoung Chul
    Ozguroglu, Mustafa
    Kojima, Takashi
    Kostorov, Vladimir
    Hierro, Cinta
    Zhu, Ying
    McLean, Lee Anne
    Shah, Sukrut
    Doi, Toshihiko
    FUTURE ONCOLOGY, 2019, 15 (10) : 1057 - 1066
  • [3] Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
    Mansoor, Wasat
    Joo, Seongjung
    Norquist, Josephine M.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chol
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Shah, Sukrut
    Shen, Lin
    ONCOLOGIST, 2024, 29 (10): : e1324 - e1335
  • [4] Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer
    Kato, K.
    Shah, M. A.
    Enzinger, P. C.
    Bennouna, J.
    Shen, L.
    Adenis, A.
    Sun, J-M.
    Cho, B. C.
    Ozguroglu, M.
    Kojima, T.
    Kostorov, V.
    Hierro, C.
    Zhu, Y.
    Shah, S.
    Bhagia, P.
    Doi, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] First-line pembrolizumab plus chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Kojima, Takashi
    Hara, Hiroki
    Tsuji, Akihito
    Yasui, Hisateru
    Muro, Kei
    Satoh, Taroh
    Ogata, Takashi
    Ishihara, Ryu
    Goto, Masahiro
    Baba, Hideo
    Nishina, Tomohiro
    Han, Shirong
    Sakata, Tomoko
    Yatsuzuka, Naoyoshi
    Doi, Toshihiko
    Kato, Ken
    ESOPHAGUS, 2022, 19 (04) : 683 - 692
  • [6] Q-TWiST analysis for pembrolizumab plus chemotherapy versus chemotherapy as first-line treatment for patients with advanced esophageal cancer in the KEYNOTE-590 study
    Diez Garcia, M.
    Shah, S.
    Joo, S.
    Valderrama, A.
    Zhang, S.
    Zhang, Y.
    Enzinger, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S348 - S348
  • [7] Pembrolizumab plus Chemotherapy as First-Line Treatment in advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGE, 2022, 28 (05): : 436 - 437
  • [8] First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Takashi Kojima
    Hiroki Hara
    Akihito Tsuji
    Hisateru Yasui
    Kei Muro
    Taroh Satoh
    Takashi Ogata
    Ryu Ishihara
    Masahiro Goto
    Hideo Baba
    Tomohiro Nishina
    Shirong Han
    Tomoko Sakata
    Naoyoshi Yatsuzuka
    Toshihiko Doi
    Ken Kato
    Esophagus, 2022, 19 : 683 - 692
  • [9] KEYNOTE-590: randomized, phase 3 study of chemotherapy plus pembrolizumab vs chemotherapy plus placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer
    Kato, Ken
    Shah, Manish
    Enzinger, Peter
    Bennouna, Jaafar
    Shen, Lin
    Adenis, Antoine
    Zhu, Ying
    Bhagia, Pooja
    Koshiji, Minori
    Doi, Toshihiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [10] Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer (May, oyae087, 2024)
    Mansoor, Wasat
    Joo, Seongjung
    Norquist, Josephine M.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chol
    Sunpaweravong, Patrapim
    Alsina, Maria
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Shah, Sukrut
    Shen, Lin
    ONCOLOGIST, 2024, 29 (08): : e1100 - e1100
12345